Illumina, Inc. (NASDAQ:ILMN) today announced that Novogene (www.novogene.cn), a leading genomics service provider based in Beijing, China, purchased one HiSeq X Ten. This strategic investment expands Novogene's capacity with Illumina's next-generation sequencing systems, which also includes HiSeqs and MiSeqs.
"The HiSeq X Ten will enhance our capability for cancer genomics and for mapping human disease genes, while enabling us to do population sequencing," said Dr. Ruiqiang Li, CEO of Novogene.
"We are excited Novogene is investing in the HiSeq X Ten to further accelerate cancer and genetic disease research in China," said Jay Flatley, CEO of Illumina. "Novogene's portfolio provides the power to conduct the full range of next-generation sequencing applications from population scale sequencing, on the HiSeq X Ten, to exomes, targeted panels and RNA applications on HiSeq and MiSeq."
The HiSeq X Ten is the world's first platform to deliver full coverage human genomes for less than $1,000, including typical instrument depreciation, DNA extraction, library preparation, and estimated labor. Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten can sequence tens of thousands of samples annually with high-quality, high-coverage sequencing. It is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than three days or up to 600 gigabases (Gb) per day, per system.
Illumina launches its first product enabling long- and short-read sequencing on one instrument